| INTRODUC TI ON
Endometrial hyperplasia is defined as an irregular proliferation of endometrial glands, characterized by an increased gland : stroma ratio compared with proliferative endometrium.
1 Endometrial hyperplasia includes benign proliferations caused by the unopposed action of estrogens and premalignant lesions, which have a considerable risk of progression to endometrial cancer. 2, 3 While benign endometrial hyperplasia may be managed by followup, premalignant endometrial hyperplasia usually requires hysterectomy, or progestins and close follow-up in selected cases. 4 However, the distinction between these two conditions is often difficult.
2
The gold standard for the differential diagnosis is the histological examination, which is based on two possible classification systems:
the World Health Organization (WHO) system and the endometrial intraepithelial neoplasia (EIN) system. 2, 3 The 2014 WHO system is based on the presence of cytological atypia and distinguishes between premalignant atypical endometrial hyperplasia and benign endometrial hyperplasia without atypia.
Nuclear atypia may include rounding, enlargement, pleomorphism, loss of polarity, and nucleoli. 1 The complexity of glandular architecture, included in the former classification (WHO, 1994), has been excluded, although it appears to be associated with higher risk of progression to endometrial cancer.
1-3
The EIN system differentiates between premalignant EIN and benign endometrial hyperplasia based on the presence of three morphological parameters (glands exceeding stroma, lesion size > 1 mm and cytological differences with adjacent non-neoplastic endometrium) and a careful exclusion of benign mimics (eg polyps and secretory endometrium) and cancer (maze-like glands, solid or cribriform areas). 2, 3, 5, 6 The EIN system classifies a considerable percentage of endometrial hyperplasia without atypia but with complex architecture as premalignant. 6 However, several concerns have been reported for the histological classification, which are related to the pathologist (low reproducibility) or to the specimen itself (tissue inadequacy, artifact changes and ambiguous features). 2, 3, 7 A great number of immunohistochemical markers have been studied to improve the reliability of the diagnosis. The anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) is upregulated through the actions of estrogens and its expression has been observed to increase in proliferative endometrium and in benign endometrial hyperplasia.
Several studies have found a loss of Bcl-2 expression in neoplastic endometrial samples (premalignant endometrial hyperplasia and endometrial cancer). 8, 9 Therefore, Bcl-2 loss has been proposed as a marker to detect intraepithelial neoplasia in endometrial specimens. 10 However the role of Bcl-2 loss of expression in endometrial carcinogenesis has never been clarified. Furthermore, its possible clinical usefulness in the differential diagnosis of endometrial hyperplasia is still subject to debate.
Thus, the aims of this study were: (i) to assess Bcl-2 immunohistochemical expression in histological specimens of proliferative endometrium, benign endometrial hyperplasia, premalignant endometrial hyperplasia and endometrial cancer, to define whether or not Bcl-2 loss of expression may be considered a marker of neoplasia; (ii) to determine the clinical usefulness of immunohistochemistry for Bcl-2 in the differential diagnosis between benign and premalignant endometrial hyperplasia, through analyses of diagnostic accuracy; and (iii) to assess how the results are influenced by the histological criteria used to classify endometrial hyperplasia and by the thresholds of Bcl-2 expression considered.
with a sensitivity of 0.18, a specificity of 0.97, a positive likelihood ratio of 5.16 and a negative likelihood ratio of 0.86. Thresholds of Bcl-2 expression not involving a complete loss showed lower diagnostic accuracy with a slight increase in sensitivity, but a severe decrease in specificity. 
Conclusions

| MATERIAL AND ME THODS
The study protocol, including methods for electronic search, study selection, risk of bias assessment, data extraction, and data analysis, was designed previously. Two authors (AT, AR) independently conducted all stages of the study; disagreements were resolved by discussion with a third author (GS). The study was reported according to the Preferred Reporting Item for Systematic Reviews and Meta-analyses statement.
MEDLINE, EMBASE, Web of Sciences, Scopus, ClinicalTrial.gov, OVID, Cochrane Library and Google Scholar were searched for relevant articles from the inception of each database to March 2018, using a combination of the following text words and all their synonyms found on Medical SubHeading (MeSH): "endometrial hyperplasia"; "proliferative endometrium"; "endometrial cancer"; "endometrial intraepithelial neoplasia"; "EIN"; "precancer"; "premalignant"; "precursor"; "Bcl2"; "Bcl 2"; "B-cell lymphoma 2"; "apoptosis"; "apoptotic"; "anti-apoptotic";
"marker"; "biomarker"; "expression"; "immunohistochemistry"; "immunohistochemical". All relevant references were also assessed. were assessed with the same index test and the same reference standard). Authors' judgments were categorized as "low risk," "high risk," or "unclear risk of bias." For the domains 1, 2, and 3, concerns about their applicability to the included studies were also assessed.
Data were extracted from the included studies without modification. Contingency 2 × 2 tables were prepared for each study, reporting two dichotomous qualitative variables: Bcl-2 expression and histological diagnosis. When discrepancies between values reported in the text and the tables were found, values from tables were used for the analysis.
The immunohistochemical expression of Bcl-2 was dichotomized into "presence" and "loss". For studies that did not dichotomize Bcl-2 expression, data were extracted using the following criteria for Bcl-2 loss:
• when Bcl-2 expression was graded according to the intensity of staining, the lowest grade, indicating absence of expression, indicated Bcl-2 loss;
• when Bcl-2 was graded according to the rate of stained cells, the lowest grade indicated Bcl-2 loss;
• when Bcl-2 expression was graded using a staining score (combining intensity and stained cells rate), the lowest grade indicated Bcl-2 loss.
The authors in one study were contacted to obtain the additional unpublished data regarding Bcl-2 expression in benign endometrial hyperplasia.
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The histological diagnosis was dichotomized as proliferative endometrium vs benign endometrial hyperplasia, benign endome- The association between the two variables (Bcl-2 expression and histological diagnosis) was assessed using odds ratios (OR), with 95% CI and a significant P value < 0.05. OR was calculated for each study and as pooled estimates, and reported graphically on forest plots.
The inconsistency index (I 2 ) was used to quantify the statistical heterogeneity among the studies: heterogeneity was considered insignificant for I 2 < 25%, low for I 2 < 50%, moderate for I 2 < 75%, and high for I 2 ≥ 75%. In case of I 2 ≥ 50%, a random effect model was adopted; otherwise, a fixed effect model was preferred.
Values of OR found in the three groups were compared by using chi-squared test, with a significant P value < 0.05.
In the analysis of diagnostic accuracy, the index test was Bcl-2 immunohistochemical expression (loss or presence), while the ref-
erence standard was endometrial hyperplasia histology (benign or premalignant). The following criteria were adopted:
• premalignant endometrial hyperplasia with Bcl-2 loss were considered true positives;
• premalignant endometrial hyperplasia with Bcl-2 presence were considered false negatives;
• benign endometrial hyperplasia with Bcl-2 loss were considered false positives;
• benign endometrial hyperplasia with Bcl-2 presence were considered true negatives.
Analyses of diagnostic accuracy were performed separately for the WHO and EIN classifications. The diagnostic accuracy was assessed as sensitivity, specificity, positive likelihood ratio (LR+), and negative likelihood ratio (LR−) with 95% CI. The area under the curve (AUC) was calculated on summary receiver operating characteristic curves. Diagnostic accuracy was considered absent for AUC ≤ 0.5, low for 0.5 < AUC ≤ 0.75, moderate for 0.75 < AUC ≤ 0.9, high for 0.9 < AUC < 0.97, and very high for AUC ≥ 0.97. A random effect model was planned previously, since a significant heterogeneity is expected in meta-analyses of diagnostic accuracy. 13 Where possible, we assessed whether the diagnostic accuracy could be improved using different thresholds of the expression of Bcl-2. Only studies considering both the intensity of staining and the rate of stained cells were suitable for such analysis.
Statistical analyses were performed using Review 
| RE SULTS
Altogether 20 observational studies 9,10,12,14-30 with a total of 1,278 specimens (137 proliferative endometrium, 676 endometrial hyperplasia, and 465 endometrial cancer), were included in the systematic review. The flow diagram reporting the process of study selection is shown in Figure 1 .
A total of 17 studies adopted the WHO classification system and three used the the EIN system. Among the studies using the WHO system, eight studies differentiated endometrial hyperplasia based on cytological atypia, six did so based on the complexity of architecture, and three did so based on both parameters.
Six studies dichotomized Bcl-2 expression, five graded the intensity of staining, three assessed the rate of stained cells, while six used more than one parameter. Out of five studies using a combined score (intensity grade +stained cells rate), two allowed extracting data for the analysis of the thresholds of Bcl-2 expression; the two scoring systems were fully comparable. 12, 30 All studies assessed the expression of Bcl-2 in endometrial glands. The characteristics of the included studies are shown in Table 1 .
The risk of bias among the included studies is shown in Figure 2 .
For the patients' selection domain, three studies were considered to be at low risk of bias (since they included consecutive patients) and 17 were at unclear risk (because they did not report selection criteria); concerns about applicability were unclear for three studies (one assessed several different human neoplasms; one included only endometrial hyperplasia treated with progestins; one selected only non-atypical endometrial hyperplasia and reclassified them according to the EIN system). For the index test domain, 10 studies were considered at low risk of bias (since they considered both intensity and distribution of immunostaining) and 10 at unclear risk (because they considered only one parameter). For the reference standard domain, six studies were considered at low risk of bias (since all specimens were re-evaluated by several authors at the same time) and 14 at unclear risk (because they did not re-evaluate the specimens). For the flow and timing domain, only one study was at unclear risk and concern (because not all endometrial hyperplasia included were assessed by immunohistochemistry), while the other 19 were considered at low risk of bias. No study was at high risk of bias. No further concerns about applicability were found.
| B-cell lymphoma 2 expression and histological diagnosis
B-cell lymphoma 2 loss was not significantly more common in benign endometrial hyperplasia than in proliferative endometrium (OR = 1.85, 95% CI, 0.86-4.02; P = 0.12), and without heterogeneity among studies (I 2 = 0%) (Figure 3a) .
Among endometrial hyperplasia, Bcl-2 loss was significantly associated with premalignant endometrial hyperplasia, according to both WHO and EIN systems:
• when the WHO system (cytological atypia) was adopted, the OR was 4.39 (95% CI, 2.56-7.53; P < 0.00001) with insignificant heterogeneity (I 2 = 22%) ( Figure 3b );
• when the EIN system was adopted, the OR was 6.07 (95% CI 1.50-24.56; P = 0.01), with no heterogeneity (I 2 = 0%) (Figure 3c ).
The difference between WHO and EIN groups was not significant (chi-squared = 0.18; P value = 0.67) (Figure 3c ).
B-cell lymphoma 2 was also significantly associated with the complexity of glandular architecture, with an OR of 2.06 (95% CI, 1.13-3.74; P value of 0.02) and without heterogeneity (I 2 = 0%).
There was no significant difference with the group of cytological atypia (chi-squared = 3.39; P value = 0.07) (Figure 3d ).
Among neoplastic samples, Bcl-2 loss was more common in endometrial cancer than in premalignant endometrial hyperplasia, without 
| Diagnostic accuracy
| WHO group
In the WHO group the sensitivity and specificity of Bcl-2 loss in detect- (Figure 4) . Analyses of different thresholds of Bcl-2 expression were not available due to the lack of studies using a scoring system that combined the intensity of staining and the rate of stained cells.
| EIN group
In the EIN group we were able to perform analyses of diagnostic accuracy for a complete loss of expression and for three differ- For threshold II (weak intensity in 33%-67% cells or moderate intensity in ≤ 33% cells), sensitivity and specificity were 0. Heterogeneity was high for sensitivity (I 2 = 77.2%), LR+ (I 2 = 84.8%) and LR− (I 2 = 87.5%), and moderate for specificity (I 2 = 74.1%).
The AUC calculation was not feasible in the analyses of expression thresholds.
| D ISCUSS I ON
Our study showed that Bcl-2 loss was significantly associated with premalignant features of endometrial hyperplasia, while no significant differences were found between proliferative endometrium and benign endometrial hyperplasia, and between premalignant F I G U R E 5 Forest plots reporting graphically diagnostic accuracy of immunohistochemical loss of B-cell lymphoma 2 expression in differentiating between benign and premalignant hyperplasia as defined by endometrial intraepithelial neoplasia criteria: (a) sensitivity; (b) specificity; (c) positive likelihood ratio; (d) negative likelihood ratio; (e) area under the curve (AUC) on summary receiver operating characteristic curves. LR, likelihood ratio [Color figure can be viewed at wileyonlinelibrary.com] endometrial hyperplasia and endometrial cancer. These findings strongly suggest that Bcl-2 loss may be a marker of endometrial neoplasia, and they are compatible with scientific evidence on Bcl-2 physiology. In fact, as Bcl-2 is under hormonal control, its expression is expected to be high in benign proliferative conditions caused by the action of estrogens such as proliferative endometrium and benign endometrial hyperplasia. 8, 9, 31 Our results showed there was a stronger association between Bcl-2 loss and the premalignant morphology of endometrial hyperplasia when the EIN system was adopted. Once it is assumed that Bcl-2 loss is a marker of precancer, such results suggest that the EIN criteria are more reliable than the WHO criteria. This observation is in agreement with several findings reported in the literature, supporting the view that the EIN system is more accurate than the WHO system in predicting progression to endometrial cancer. 2, 3, 6 However, the difference between the OR found in the two groups was not significant (P = 0.67). EIN criteria of premalignancy include glandular crowding, lesion size > 1 mm, different cytology from the adjacent endometrium, exclusion of mimics and cancer. 3 On the other hand, the WHO system is based on cytological atypia alone, and the complexity of glandular architecture has been disregarded. The value of Bcl-2 may be confirmed by its evaluation as a prognostic marker of progression to cancer. In fact, we found only one study that assessed Bcl-2 as a marker of the progression of endometrial hyperplasia to endometrial cancer, showing a significant association between a decreased expression (rate of stained cells ≤ 80%) and the subsequent development of endometrial cancer.
33
As Bcl-2 expression may not decrease simultaneously in glands and stroma 34 it would be interesting to study the possible relevance of Bcl-2 stromal expression in the differential diagnosis of endometrial hyperplasia. Nevertheless, given the recent discoveries on the genetics of endometrial cancer, the need for a molecular definition of endometrial neoplastic specimens has been growing, as well as the search for cheaper immunohistochemical surrogates of genetic prognostic markers. 35 Thus, the importance of Bcl-2 and other immunohistochemical markers may be set to increase in the near future.
To the best of our knowledge, this study may be the first meta-analysis assessing the expression of Bcl-2 in endometrial hyperplasia. We defined the association of Bcl-2 loss with the neoplastic nature of endometrial hyperplasia, and the accuracy of immunohistochemistry for Bcl-2 in a differential diagnosis between benign and premalignant endometrial hyperplasia.
Furthermore, we assessed the influence of the histological criteria adopted on the results, and we interpreted the results based on the scientific evidence reported in the literature. On the other hand, one limitation of our study may be found in the low uniformity of the methods among the included studies. In fact, several differences were found with regard to the baseline characteristics of the patients (such as age and body mass index) and the type of sample (such as hysteroscopic biopsy, curettage, or surgical specimen). The selection criteria for participants differed among the studies, and in most cases they were not specified ( Figure 2 ). Further studies in this field should include consecutive patients to avoid spectrum bias.
Histological slides were reviewed simultaneously by at least two pathologists in fewer than 50% of the included studies, creating a possible bias in the reference standard ( Figure 2 ). However, statistical heterogeneity among studies was low or absent in most of our analyses, giving solidity to our results. High heterogeneity was observed only for the diagnostic accuracy analysis, where it is expected.
13
Another limitation may consist in the absence of a validated method to interpret Bcl-2 immunostaining in terms of the intensity of the staining and the rate of stained cells. Nonetheless, we considered only a complete loss of Bcl-2 expression in the main analysis, limiting the risk of bias caused by the low reproducibility of a qualitative scoring. Moreover, for the assessment of the different thresholds of Bcl-2 expression, we limited the analysis only to studies adopting a complete and clearly defined scoring system, which considered both the intensity of the staining and the rate of the stained cells.
| CON CLUS ION
A loss of immunohistochemical expression of Bcl-2 in endometrial hyperplasia is significantly associated with premalignancy, regardless of the classification system adopted. When assessed with the EIN criteria, Bcl-2 loss appeared as a highly specific marker of endometrial precancer, with high diagnostic accuracy. Thus, the finding of Bcl-2 loss in endometrial hyperplasia might be a novel indication for treatment and follow-up, especially when precancerous features are ambiguous at histological examination. Thresholds of Bcl-2 expression that differ from a complete loss showed a lower diagnostic accuracy and their use
should not be considered. Our results also suggest that EIN classification system is more reliable than the WHO system, suggesting that the complexity of glandular architecture as a premalignant feature is an important criterion. However, further studies examining Bcl-2 loss as independent prognostic factor are needed to use this certain marker for treatment in the absence of overt precancerous features in histological examination.
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